Key Highlights

  • Clarity Pharmaceuticals has become one of the most closely watched names on the ASX healthcare board, and recent trial disclosures help explain
  • The company works in one of medicine's fastest-growing niches: pairing a diagnostic imaging agent with a matched therapeutic, both built around copper
  • On 5 August 2026, Clarity reported an update from its SECuRE therapy trial of 67Cu-SAR-bisPSMA in men with metastatic castration-resistant prostate cancer.
  • The company also reported two additional complete responses in the cohort-expansion phase, bringing the program total to seven, five of them in

Clarity Pharmaceuticals has become one of the most closely watched names on the ASX healthcare board, and recent trial disclosures help explain why. The Sydney-based radiopharmaceutical developer is advancing its copper-based "Targeted Copper Theranostics" platform through late-stage clinical testing, and 2026 has delivered the kind of milestones that move such stories from early promise toward genuine clinical validation.

The company works in one of medicine's fastest-growing niches: pairing a diagnostic imaging agent with a matched therapeutic, both built around copper isotopes. Its lead Assets target prostate-specific membrane antigen (PSMA), a protein highly expressed in prostate cancer, positioning Clarity in the same broad field that has attracted large pharmaceutical interest globally.

The SECuRE therapy data

On 5 August 2026, Clarity reported an update from its SECuRE therapy trial of 67Cu-SAR-bisPSMA in men with metastatic castration-resistant prostate cancer. In the 8 GBq dose cohort of 19 participants, 74% achieved a PSA25 response and 63% achieved a PSA50 response, with 53% reaching PSA75 and 26% reaching PSA90. Among radiographically evaluable patients, 81% achieved disease control.

The company also reported two additional complete responses in the cohort-expansion phase, bringing the program total to seven, five of them in the 8 GBq cohorts. Notably, these results came in a heavily pre-treated population, with 79% of participants having received five or more prior anti-cancer regimens. On safety, most related adverse events were mild-to-moderate and transient, commonly dry mouth and nausea, with no Grade 4 or higher related events reported.

The registrational step

The word "pivotal" is doing real work here. Clarity has commenced a Phase III registrational trial, CLARIFY, evaluating its Cu-64 SAR-bisPSMA imaging agent, and the diagnostic program has also received US FDA Fast Track Designation in the biochemical-recurrence setting. A registrational study is the stage designed to support regulatory approval, so the transition from earlier-phase work to a Phase III trial marks a meaningful escalation in both ambition and scrutiny.

Earlier in 2026, Clarity presented positive prostate-cancer data at the EANM Congress, adding to the body of evidence around its imaging candidate.

Why it matters to investors

For a pre-revenue clinical developer, value is created by de-risking assets through successive trial readouts and regulatory milestones. The combination of a registrational imaging trial and encouraging therapy responses gives Clarity two shots on goal within the same PSMA franchise. If the diagnostic secures approval, it could also help identify and monitor patients suited to the therapeutic, reinforcing the theranostic thesis.

Catalysts to watch

Several events could shape sentiment. Progress and any interim readouts from the CLARIFY Phase III program are central. So too is the pathway for the 67Cu-SAR-bisPSMA therapy toward its own later-stage trial, given the response data reported to date. Investors will also watch cash runway and any Manufacturing or supply-chain steps needed to scale copper-based products, an area the company has flagged as strategically important.

Key risks

The risks are those common to clinical-stage biotech. Early efficacy signals do not guarantee success in larger, controlled trials; regulatory approval is never assured; and radiopharmaceutical companies face isotope-supply and manufacturing complexity that established drugs do not. As a pre-profit business, Clarity is also exposed to capital-markets conditions and may need further funding.

On balance, the verified 2026 disclosures support the view that Clarity is moving into a more decisive phase of its development. The therapy data are early but encouraging, and the registrational imaging trial is a concrete step toward commercialisation. Whether that potential is realised now rests on data that has yet to be generated.